D’Amelio to retire as Pfizer’s CFO

Frank D’Amelio will retire from Pfizer Inc. (NYSE:PFE) as CFO and EVP of global supply after nearly 15 years. During his tenure, the company said it generated nearly $150 billion in market cap growth, due in part to acquisitions and partnerships valued at $200 billion that were led by D’Amelio, including the acquisition of Wyeth. Most recently, D’Amelio oversaw Pfizer’s manufacturing network to address the COVID-19 crisis. D’Amelio will stay on the board and serve in a consulting role while the company searches for the new CFO. Additionally, Mike McDermott was named EVP and chief global supply officer, effective Jan.1, 2022. McDermott held various senior roles at the company, most recently as president of Pfizer’s global supply.

Longevity company BioAge Labs Inc. hired Dov Goldstein as CFO and Ann Neale as CDO. Goldstein was chief financial and business officer at Indapta Therapeutics Inc., and Neale was SVP of development operations at Principia Biopharma, which was acquired by Sanofi (Euronext:SAN; NASDAQ:SNY) for $3.6 billion...